Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

MDNA 413

Next Previous
Drug Profile

MDNA 413

Alternative Names: Fc-MDNA413; MDNA-413

Latest Information Update: 07 Aug 2025

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Stanford University
  • Developer Medicenna Therapeutics; Stanford University
  • Class Antineoplastics; Cytokines; Interleukins; Recombinant fusion proteins
  • Mechanism of Action Interleukin-4 receptor type II antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • No development reported Asthma; Atopic dermatitis; Solid tumours

Most Recent Events

  • 31 Jul 2025 Medicenna Therapeutics has patent protection for “Method of Producing Th9 T Cells” in the US, Switzerland, Germany, France, United Kingdom, India, and Japan. [In-licensed from Stanford]
  • 28 Apr 2023 No recent reports of development identified for preclinical development in Solid-tumours in USA
  • 22 Sep 2022 Pharmacodynamics data from a preclinical study in Solid tumours presented at the 10th Annual Meeting of the International Cytokine & Interferon Society (Cytokines-2022)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top